Advertisement

EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?

  • Raffaella MormileEmail author
Letter to the Editor
  • 45 Downloads

Notes

Compliance with Ethical Standards

Conflict of Interest

The author declares no conflict of interest.

References

  1. 1.
    Oshima Y, Tanimoto T, Yuji K, Tojo A (2018) EGFR-TKI-associated interstitial pneumonitis in Nivolumab-treated patients with non-small cell lung Cancer. JAMA Oncol 4(8):1112–1115CrossRefGoogle Scholar
  2. 2.
    Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C (2016) Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Expert Rev Clin Pharmacol 9(12):1571–1581CrossRefGoogle Scholar
  3. 3.
    Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K (2017) EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf 16(4):465–469CrossRefGoogle Scholar
  4. 4.
    Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE et al (2018) Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J Thorac Oncol 13(9):1363–1372Google Scholar
  5. 5.
    Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K et al (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28(7):1532–1539CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Division of Pediatrics and NeonatologyMoscati HospitalAversaItaly

Personalised recommendations